Pharma & Biotech Events & Conferences
Refine Search
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Biotechnology
US pharma major Bristol-Myers Squibb today announced results from the open-label switch period of Early AMPLE, a Phase IV exploratory biomarker study assessing the differences by which Orencia (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients who tested positive (seropositive) for certain autoantibodies. 3 June 2020
Biotechnology
Regeneron and Sanofi have presented new data on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer. 1 June 2020
Biotechnology
Updated analysis of the Phase III CASPIAN trial showed Imfinzi (durvalumab) alongside a choice of chemotherapies demonstrated a sustained, clinically-meaningful overall survival (OS) benefit as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). 1 June 2020
Biotechnology
Detailed results from the Phase III ADAURA trial released for the first time showed that Tagrisso (osimertinib) demonstrated a statistically-significant and clinically-meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. 29 May 2020
Biotechnology
New data in bladder cancer could help make Bavencio (avelumab) more than just an also ran in checkpoint inhibition. 29 May 2020
Pharmaceutical
Swiss pharma major Novartis has announced a new exploratory subgroup analysis from the Phase III MONALEESA-3 and MONALEESA-7 trials, to be presented during the ASCO20 Virtual Scientific Program. 27 May 2020
Pharmaceutical
At this year’s ASCO, positive Phase III data for Erleada (apalutamide) in prostate cancer will boost prescriber confidence in the therapy, building on datasets presented at last year’s event. 14 May 2020
Biotechnology
Ahead of featuring the data at the American Society of Clinical Oncology (ASCO) meeting later this month, results from the Phase III CheckMate-9LA trial, which demonstrated a statistically-significant and clinically-meaningful survival benefit with Opdivo (nivolumab) plus Yervoy (ipilimumab), given concomitantly with two cycles of chemotherapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC), have been released. 14 May 2020
Pharmaceutical
Reaching into every part of professional and personal life, the coronavirus pandemic has turned the world on its head, making old certainties seem fragile while forcing change from every corner. 1 May 2020
Biotechnology
UK-based clinical-stage biotech Axon Neuroscience presented positive results of its Phase II trial for AADvac1, the first tau vaccine to treat and prevent Alzheimer's disease, at the AAT-AD/PD (International Conference on Alzheimer’s & Parkinson’s Diseases) 2020 conference, Vienna, Austria. 3 April 2020
Pharmaceutical
A new sub-analysis of the landmark Phase III DAPA-HF trial has showed positive efficacy for Farxiga (dapagliflozin) in treating cardiovascular conditions. 30 March 2020
Pharmaceutical
New data has been presented on vericiguat, an orally-administered soluble guanylate cyclase (sGC) stimulator being developed to treat patients with heart failure with reduced ejection fraction and following a worsening event. 30 March 2020
Biotechnology
Novartis has announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. 30 March 2020
Biotechnology
Data published at a virtual Clinical Trial Session, conducted by the Muscular Dystrophy Association (MDA), show Zolgensma (onasemnogene abeparvovec-xioi) produced significant benefit to people with spinal muscular atrophy (SMA). 24 March 2020
Pharmaceutical
At the annual meeting of the American Society of Hematology (ASH), French drugmaker Sanofi presented positive data for ex-Bioverativ asset sutimlimab. 11 December 2019
Pharmaceutical
At the 2019 ASH annual meeting, Bristol-Myers Squibb has announced positive results from the QUAZAR AML-001 study of an experimental oral hypomethylating agent, CC-486. 10 December 2019
Biotechnology
US pharma major Bristol-Myers Squibb presented data from multiple studies evaluating Reblozyl (luspatercept-aamt) in patients with anemia associated with multiple serious blood diseases at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. 10 December 2019
Pharmaceutical
Shares of US biotech firm ArQule spiked 102% to $19.60 in Monday pre-market trading, after it was revealed that it has received a takeover offer from US pharma giant Merck & Co. 9 December 2019
Biotechnology
US pharma major Bristol-Myers Squibb announced over the weekend that its Phase I study of lisocabtagene maraleucel (liso-cel) met its primary and secondary endpoints while demonstrating durable responses. 9 December 2019
Biotechnology
US biotech bluebird bio has presented new data from its Phase I/II HGB-206 study of its LentiGlobin gene therapy for sickle cell disease (SCD) at ASH. 9 December 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze